1. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
- Author
-
Javier Fernández-Mateos, Andrea Sottoriva, Carlo C. Maley, Inmaculada Spiteri, Udai Banerji, Benjamin Werner, Ahmet Acar, Mark Stubbs, Luca Magnani, Sung Pil Hong, Giulio Caravagna, Adam Stewart, Nicholas A. Trahearn, Daniel Nichol, Nicola Valeri, Georgios Vlachogiannis, Rosemary Burke, George D. Cresswell, Iros Barozzi, Acar, A., Nichol, D., Fernandez-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., Stewart, A., Caravagna, G., Werner, B., Vlachogiannis, G., Maley, C. C., Magnani, L., Valeri, N., Banerji, U., and Sottoriva, A.
- Subjects
0301 basic medicine ,Lung Neoplasms ,EGFR BLOCKADE ,Stochastic Processe ,TUMOR HETEROGENEITY ,Drug Resistance ,General Physics and Astronomy ,Drug resistance ,Pyridone ,Genome informatics ,Somatic evolution in cancer ,Antineoplastic Agent ,0302 clinical medicine ,TARGETED THERAPY ,Theoretical ,Models ,lcsh:Science ,Stochastic modelling ,media_common ,Pyrimidinone ,education.field_of_study ,Multidisciplinary ,Gefitinib ,3. Good health ,Multidisciplinary Sciences ,030220 oncology & carcinogenesis ,Science & Technology - Other Topics ,Molecular Medicine ,Lung cancer ,medicine.drug ,Human ,Drug ,Genotype ,Evolution ,Pyridones ,media_common.quotation_subject ,Science ,CELL LUNG-CANCER ,Population ,COMPETITION ,Antineoplastic Agents ,Computational biology ,Pyrimidinones ,Biology ,Clonal Evolution ,Computational Biology ,Computer Simulation ,Humans ,Models, Theoretical ,Stochastic Processes ,Drug Resistance, Neoplasm ,Evolution, Molecular ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,medicine ,Sensitivity (control systems) ,Evolutionary dynamics ,education ,Science & Technology ,MUTATIONS ,Cancer ,Molecular ,General Chemistry ,medicine.disease ,Lung Neoplasm ,030104 developmental biology ,COPY NUMBER ,Computer modelling ,Neoplasm ,lcsh:Q ,INHIBITORS ,ACQUIRED-RESISTANCE - Abstract
Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 108–109 cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance., Evolutionary steering uses therapies to control tumour evolution by exploiting trade-offs. Here, using a barcoding approach applied to large cell populations, the authors explore evolutionary steering in lung cancer cells treated with EGFR inhibitors.
- Published
- 2020